Telix Pharmaceuticals Ltd.
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 01/09/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Telix Pharmaceuticals Ltd. |
| Case Number: | Case Number: 1:25cv02299 |
| Class Period: | Class Period: 02/21/2025 - 08/28/2025 |
| Ticker: | Ticker: TLX |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix's supply chain and partners; and (3) as a result, defendants statements about Telix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.